Shares of Incyte Corp. rallied 4.83% to $70.81 Thursday, on what proved to be an all-around positive trading session for the ...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) recently announced the appointment of Dr. Pushkal Garg as Executive Vice President and Chief Research and Development Officer to accelerate its R&D efforts.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

A high-level overview of Alnylam Pharmaceuticals, Inc. (ALNY) stock. View (ALNY) real-time stock price, chart, news, analysis, analyst reviews and more.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the polyneuropathy manifestations of ATTR amyloidosis and hereditary transthyretin ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Thirty-three life sciences companies are slated to receive $29.9 million in tax incentives for creating 1,519 new industry ...